Literature DB >> 20629165

Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning.

Nanda Reedeker1, Rose C Van Der Mast, Erik J Giltay, Erik Van Duijn, Raymond A C Roos.   

Abstract

Besides chorea, hypokinesia is an important motor disturbance in Huntington's disease (HD) but its clinical, neuropsychiatric, and cognitive functioning correlates are largely unknown. This cross-sectional study investigates correlates of hypokinesia in HD and its effect on global functioning. Among 150 HD gene carriers, 96 patients were clinically motor manifest. Hypokinesia was assessed using the motor section of the Unified Huntington's Disease Rating Scale and global functioning was measured using the Total Functioning Capacity (TFC) scale. Neuropsychiatric measures included the Apathy Scale and the Composite International Diagnostic Interview for diagnosis of depression. The Mini Mental State Examination (MMSE) and a composite executive cognitive measure were used to assess global and executive cognitive functioning, respectively. Compared with 45 patients with no or mild hypokinesia, 51 patients with moderate to severe hypokinesia showed a significant difference in most clinical and neuropsychiatric variables and had worse cognitive functioning scores. However, using forward logistic regression analysis, poor executive cognitive functioning was the only independent correlate of hypokinesia (OR 7.33; 95% CI: 2.82-19.0; P < 0.001). Hypokinesia score was inversely associated with the TFC score (P < 0.001), also after adjusting for chorea, use of antipsychotics, apathy, and global and executive cognitive functioning. In conclusion, the presence of moderate to severe hypokinesia in HD patients co-occurs with executive cognitive dysfunction and adversely affects global functioning.

Entities:  

Mesh:

Year:  2010        PMID: 20629165     DOI: 10.1002/mds.23136

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Tracking motor impairments in the progression of Huntington's disease.

Authors:  Jeffery D Long; Jane S Paulsen; Karen Marder; Ying Zhang; Ji-In Kim; James A Mills
Journal:  Mov Disord       Date:  2013-10-21       Impact factor: 10.338

2.  Clinical and genetic investigation of a Brazilian family with Huntington's disease.

Authors:  L A Agostinho; M Spitz; J S Pereira; C L A Paiva
Journal:  Funct Neurol       Date:  2016 Jul-Sep

3.  Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.

Authors:  M Jacobs; E P Hart; E W van Zwet; A R Bentivoglio; J M Burgunder; D Craufurd; R Reilmann; C Saft; R A C Roos
Journal:  J Neurol       Date:  2016-07-19       Impact factor: 4.849

Review 4.  Lessons learned from the transgenic Huntington's disease rats.

Authors:  Rinske Vlamings; Dagmar H Zeef; Marcus L F Janssen; Mayke Oosterloo; Frederic Schaper; Ali Jahanshahi; Yasin Temel
Journal:  Neural Plast       Date:  2012-07-18       Impact factor: 3.599

Review 5.  Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.

Authors:  Susanna Waters; Joakim Tedroff; Henrik Ponten; Daniel Klamer; Clas Sonesson; Nicholas Waters
Journal:  J Huntingtons Dis       Date:  2018

6.  Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic-rigid motor subtypes in Huntington's disease.

Authors:  Jannis Achenbach; Sarah Maria von Hein; Carsten Saft
Journal:  Brain Behav       Date:  2020-06-12       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.